🇺🇸 FDA

Intelligence Platform

Patents

Browse 2,828 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10485844

Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10478435

Use of CRAC channel inhibitors for the treatment of stroke and traumatic brain injury

United States Government as represented by the Department of Veterans Affairs · Granted Tue Nov 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10479784

Substituted pyrazin-2-amines as inhibitors of ATR kinase

Vertex Pharmaceuticals Incorporated · Granted Tue Nov 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10479798

Six-membered ring benzo derivatives as DPP-4 inhibitor and use thereof

East China University of Science and Technology · Granted Tue Nov 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10478430

Compounds useful as inhibitors of ATR kinase and combination therapies thereof

Vertex Pharmaceuticals Incorporated · Granted Tue Nov 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10479786

Protein kinase inhibitors

Princeton Drug Discovery, Inc · Granted Tue Nov 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10472387

Inhibitors of glucocorticoid receptor

ORIC PHARMACEUTICALS, INC. · Granted Tue Nov 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10471142

Combination therapy using immunoglobulin and C1-Inhibitor

THE GOVERNMENT OF THE UNITED STATES OF AMERICA · Granted Tue Nov 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10471051

Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer

Asana BioSciences, LLC · Granted Tue Nov 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10471055

Methods of treating cancer patients with farnesyltransferase inhibitors

Kura Oncology, Inc. · Granted Tue Nov 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10471061

Galactokinase inhibitors for the treatment and prevention of associated diseases and disor

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Nov 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10463652

Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions there

VTV THERAPEUTICS LLC · Granted Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10463663

Pyridazinone compounds and their use as DAAO inhibitors

Takeda Pharmaceutical Company Limited · Granted Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10457725

Methods of treating skin cancer by administering a PD-1 inhibitor

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10449182

Sorafenib derivatives as p21 inhibitors

The Regents of the University of California · Granted Tue Oct 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10450285

2-benzoylaminobenzamide derivatives as Bcl-3 inhibitors

University College Cardiff Consultants Limited · Granted Tue Oct 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10451610

Prediction of response to PARP inhibitors and combinational therapy targeting C-MET and PA

The Board of Regents of the University of Texas System · Granted Tue Oct 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10448637

Inhibitors of GRB2-associated binding protein 1 (GAB1) and methods of treating cancer usin

Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue Oct 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10450572

Androgen receptor variant inhibitors and methods of using

Regents of the University of Minnesota · Granted Tue Oct 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10441586

CRMP2 SUMOylation inhibitors and uses thereof

Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue Oct 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10442791

DNA-PK inhibitors

Vertex Pharmaceuticals Incorporated · Granted Tue Oct 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10435355

Inhibitors of fatty acid amide hydrolase (FAAH) enzyme with improved oral bioavailability

The Regents of the University of California · Granted Tue Oct 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10434100

Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes

Lixte Biotechnology, Inc. · Granted Tue Oct 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10435399

HDAC6 inhibitory heterocyclic compound

Takeda Pharmaceutical Company Limited · Granted Tue Oct 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted